Publications by authors named "Edward Piper"

Claim this Profile
T
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
Reynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, Peter Wessman, Karin Bowen, Edward Piper

Lancet Respir Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.
Paul Baverel, Dewei She, Edward Piper, Shinya Ueda, Tomoko Yoshioka

Drug Metab Pharmacokinet· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma.
Christopher E Brightling, Lars H Nordenmark, Meena Jain, Edward Piper, Dewei She

Am J Respir Crit Care Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.
Paul G Baverel, Meena Jain, Iwona Stelmach, Dewei She, Balaji Agoram, Edward Piper

Br J Clin Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Christopher E Brightling, Pascal Chanez, Richard Leigh, Paul M O'Byrne, Stephanie Korn, Edward Piper

Lancet Respir Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.
Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni

Eur Respir J· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia.
Evan A Stein, Harold Bays, Dennis O'Brien, Jim Pedicano, Edward Piper

Circulation· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis